‘Inverse' vaccines may hold key to challenge autoimmune diseases
However, these injections work differently from conventional immunizations like the flu shot and currently available immunosuppressant treatments for autoimmune conditions.
They work by targeting only the specific part of the immune system that's behind diseases such as lupus, multiple sclerosis, psoriasis, rheumatoid arthritis and Type 1 diabetes, the experts say.
'Inverse vaccines are being developed to treat undesired immune responses, [and] for these situations, the body is reacting to something that is not dangerous,' said Lonnie Shea, a researcher in biomedical engineering at the University of Michigan who has studied inverse vaccines and worked on some of the key technology behind them.
'A vaccine activates an immune response to a specific antigen,' Shea told UPI via email. Inverse vaccines are being developed to treat undesired immune responses, [and] for these situations, the body is reacting to something that is not dangerous.
Essentially, an inverse vaccine 'aims to decrease the response to a specific antigen, like insulin in Type 1 diabetes,' he added.
First line of defense
When healthy, the immune system is the body's first line of defense against diseases such as cancer and infections caused by viruses and bacteria, according to the National Institutes of Health.
However, if the immune system isn't working properly, it can erroneously attack healthy cells, tissues and organs, causing autoimmune diseases that can affect any part of the body, weakening function and potentially leading to death, the NIH says.
More than 80 autoimmune diseases are known, some of which are caused by exposure to environmental toxins and have no discovered cure. At least 15 million people in the United States, or about 5% of the population, have an autoimmune disease, the agency reports.
Although no cure exists for these conditions, symptoms can be managed with drugs called immunosuppressants, which as the name suggests 'broadly reduces your immune system response,' Shea said.
These drugs, which are typically administered via monthly injections, can have significant side effects, including making those taking them more susceptible to infections, according to the NIH.
Many people taking them also have to be careful taking traditional vaccines, such as flu shot or COVID-19 shots because of their impact on the immune system.
Training the immune system
Developed by researchers at the University of Chicago and elsewhere, inverse vaccines use synthetic nanoparticles attached to specific disease-related proteins, or antigens, to train certain parts of the immune system to behave differently, limiting the attacks that cause autoimmune diseases, neurologist Dr. Lawrence Steinman said.
With the inverse vaccines currently being studied, the nanoparticles are designed to mimic human cell death, which is a normal process in the human body, according to the 2021 study that first documented their effectiveness in people with celiac disease, another autoimmune disorder.
Dying cells are considered foreign bodies, but the human immune system knows not to attack them.
As a result, with the nanoparticles in inverse vaccines, the immune system can be trained not to attack them, or the proteins attached to them, which effectively short-circuits the process behind autoimmune diseases, Steinman said.
'Instead of immunizing the recipient to a viral infection, the inverse vaccine tolerizes the immune system, so it will not attack our own tissues,' Steinman, who has written about inverse vaccines, told UPI in an email.
Several companies are running clinical trials of inverse vaccines, including Cour Pharma, which recently completed successful phase 2 clinical trials for their use in celiac disease and another autoimmune disease, primary biliary cholangitis, according to Shea at the University of Michigan, one of the researchers who started the company.
Additional trials -- phase 2 studies are the second stage in the drug research and development process -- are starting for myasthenia gravis and Type 1 diabetes, he added.
Although more research is needed before the shots become available, a process that could take five years or more, inverse vaccines offer key advantages, Shea said.
For example, unlike immunosuppressants with their monthly dosing, the effects of inverse vaccines appear to last longer, perhaps for as much as a year, similar to conventional vaccines, research suggests.
They may also work for people with severe, life-threatening allergies, such as peanut allergies, according to Shea, who has published a study in this area using mice.
However, there's also the 'risk that instead of tolerizing the human immune system to the target, the process induces conventional immunization, which would make autoimmune conditions like Type 1 diabetes and multiple sclerosis worse,' Steinman said.
However, 'We have come close to success in some early-stage trials,' he said 'Thus far, none of the results are sufficiently robust for submission in the FDA approval process.'
Copyright 2025 UPI News Corporation. All Rights Reserved.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
3 hours ago
- Chicago Tribune
Daywatch: Once lost, Purple Heart is back with family of Peoria veteran
Good morning, Chicago. Nearly 81 years to the date after 20-year-old Army Pfc. John L. Moore was wounded while fighting to liberate Europe during WWII, the Purple Heart he earned that day is now in the hands of his only surviving sibling. Jerry Moore was little more than a toddler when his brother went off to war. Now 86, Moore held the heart-shaped medal for what he said was the first time after Illinois Treasurer Michael Frerichs presented it to him yesterday at the World War II memorial in Decatur. The poignant ceremony, which included the Macon County Honor Guard, was held just days before the Independence Day holiday weekend. 'It means a lot to my heart,' said Jerry Moore, fighting back tears. 'I don't think there can be any higher honor than getting this back.' Read the full story from the Tribune's Christy Gutowski. Here are the top stories you need to know to start your day, including a look back at a suburban company's role in the creation of DeLorean time machine, why Cook County political leaders are pointing fingers over tech troubles and which Chicago players were named All-Star Game starters. Today's eNewspaper edition | Subscribe to more newsletters | Asking Eric | Horoscopes | Puzzles & Games | Today in History A drive-by mass shooting killed four people and wounded 14 more late last night on the near North Side, Chicago police said. The shooting took place around 11 p.m. yesterday and little detail was available this morning. A large group of people were on the 300 block of West Chicago Avenue when people inside a dark vehicle drove past, fired into the crowd and drove away, police said. The government's top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding recommendations from government scientists, according to federal documents released yesterday. The new memos from the Food and Drug Administration show how the agency's vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and Moderna. The Chicago versus downstate dynamic has been a source of friction in state politics for years, and Gov. JB Pritzker's choice figures to play into that issue going forward. For his part, Christian Mitchell said he is ready to meet people from all over Illinois. On the 40th anniversary of the 'Back to the Future' movie premiere, Northbrook-based insurance giant Allstate is traveling back to the past to reveal its little-known role in developing the DeLorean, the futuristic but short-lived, gull-winged, stainless steel car that served as Doc Brown's time machine. Without Allstate, Marty McFly might never have left 1985 or perhaps he would have traveled back in time in a Buick, forever disrupting the space-time continuum of the seminal movie trilogy. Cook County property tax bills already on track to be at least one month tardy may arrive even later as controversial contractor Tyler Technologies' upgrades to the countywide property tax systems are again running behind schedule, leading to mounting frustration and political fighting among county leaders. Cook County Board President Toni Preckwinkle's office yesterday published the first of what is expected to be several reports detailing the technology delays and assigning blame for whether the fault lies with Tyler or with Assessor Fritz Kaegi, Treasurer Maria Pappas or Clerk Monica Gordon, the three county officeholders who handle property taxes. The family of slain Chicago police Officer Krystal Rivera is calling for city agencies to relinquish the investigation of her death and, instead, turn over the probe to the Illinois State Police as they pursue legal avenues. The slain officer's parents and their attorney also asked that the city release the body-worn camera footage that captured the fatal June 5 shooting — despite a standing order from a Cook County judge preventing the public release. A jury found a former Chicago Public Schools dean guilty of multiple felony counts for sexually abusing a student, after the young woman testified that he coerced her into a relationship years earlier while she attended a Little Village high school. For the first time in nearly 90 years, the Chicago Cubs will have two outfielders in the starting lineup at the All-Star Game. Center fielder Pete Crow-Armstrong and right fielder Kyle Tucker earned enough votes in the second phase of the process, which ran from Monday until 11 a.m. yesterday, to be named National League starters for the Midsummer Classic on July 15 at Truist Park in Atlanta. Sean 'Diddy' Combs was convicted yesterday of prostitution-related offenses under the federal Mann Act, an anti-sex trafficking law with a controversial, century-old history. Here's what to know about the law. The longest, strangest trip embarked upon by a rock 'n' roll band ended 30 years ago this week at Soldier Field. On July 9, 1995, the Grateful Dead played what would be its final concert with its full lineup at the stadium — the harmonious echoes of 'Box of Rain' concluding a fascinating musical journey that began in May 1965 at a small pizza parlor in California and encompassed more than 2,300 shows. This will be a great big for many of you, particularly armchair architecture historians, professional historians and anyone who ever took an architecture boat tour and now has strong opinions about bricks — but Christopher Borrelli didn't really know why the Wrigley gave off such odd vibes until he read 'The Wrigley Building: The Making of an Icon,' a fascinating and pretty entertaining new $95 coffee table book devoted to this terra cotta mainstay.
Scientific American
3 hours ago
- Scientific American
U.S. Budget Cuts Are Robbing Early-Career Scientists of Their Future
As a young doctoral researcher at a university in the southern U.S., Camilo felt like he was finally closing in on his dream of becoming a leader in the next generation of HIV scholars. His recent work has helped hundreds of LGBTQ+ Latino people access HIV prevention programs and preexposure prophylaxis, or PrEP, a medication that reduces HIV infection risk. But these lifesaving efforts—and Camilo's hopes of a career focused on directly helping people in his community—came to a screeching halt one recent Friday afternoon: he opened an e-mail that said a National Institutes of Health grant, vital to his work, had been terminated. 'I saw an image of a floating pair of scissors clipping my future,' says Camilo, who asked to use a pseudonym, citing fear of retaliation. Since researchers first began receiving grant termination letters in late February, massive chunks of federal funding for science and health have been canceled on a near-weekly basis. The Trump administration has framed these cuts as a way to reduce wasteful spending, refocus research priorities and eliminate ideological bias. Grants have been flagged for containing keywords such as 'women,' 'diverse,' 'minority' and 'racially.' Camilo's research checked all the boxes for the administration's crackdown on so-called diversity, equity and inclusion (DEI) research. He had been expecting the bad news, but when it came, it was still crushing. 'You're losing everything,' he says. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. Grant Watch, a project tracking Trump's scientific funding cancellations, has tallied more than 2,482 terminated NIH grants worth $8.7 billion and 1,669 terminated National Science Foundation grants worth $1.5 billion as of mid-June. An NSF spokesperson declined an interview request from Scientific American but wrote in an e-mail that 'we remain committed to awarding grants and funding all areas of science and engineering.' The Department of Health and Human Services did not respond to direct requests for an interview for this article. An NIH representative did not respond to a list of written questions but said the agency 'is taking action to terminate research funding that is not aligned with NIH and HHS priorities.' 'I saw an image of a floating pair of scissors clipping my future.' —Camilo, doctoral researcher On June 16 Judge William Young of the U.S. District Court for the District of Massachusetts ruled against cuts to hundreds of grants for projects through the NIH, calling these cuts 'void and illegal' and indicating that funding must be reinstated. Experts expect the Trump administration will appeal the ruling, which does not apply to all of the terminated grants compiled by Grant Watch. Virtually every research sector has been disrupted in some way since Trump took office and issued a slew of executive orders affecting science and health care. Tens of thousands of federal employees at the HHS, NIH and other science- and health-related agencies have been laid off. Universities are bracing for major federal funding cuts by freezing new hiring and cutting graduate student positions. Private research companies and industries have also seen some federal support severed—including support for the development of new vaccines and cancer treatments. 'When you cut fellowships and grants, you're cutting the people that are doing the work.' —Andrew Pekosz, virologist, Johns Hopkins University Of the many thousands of researchers grappling with the fallout, one group is being disproportionately affected: early-career scientists. Senior researchers often have a diversity of funding streams, but for those starting out in the field, 'grants serve as the foundation for an entire career of work,' says Megan Ranney, dean of the Yale School of Public Health. With the cuts, 'there are some [early-career researchers] who we will undoubtedly lose from the scientific and health enterprises.' Scientific American posted on a Reddit space for scientists, researchers and lab workers to ask people how they are grappling with the professional and personal whiplash of these interruptions. More than 50 people responded with public comments; dozens more sent private messages expressing fears, frustrations and concerns. We interviewed several of them—and other junior researchers—about how the cuts are affecting their current and future work and what the long-term consequences may be for the U.S. Research Interrupted Students and postdoctoral researchers perform the vast majority of research at academic institutions, so in addition to disrupting individual lives, the cuts have thrown whole laboratories into disarray. 'When you cut fellowships and grants, you're cutting the people that are doing the work,' says Andrew Pekosz, a virologist who leads a lab at the Johns Hopkins Bloomberg School of Public Health. Pekosz's lab had recently lost a COVID-related grant that was supposed to run until September. which forced him to dismiss a postdoc and a research associate because he lacked funding for their salaries. He was able to cobble together support for a Ph.D. student on the project but had to shorten the timeline for the research. Although the lab's grant is among those that Judge Young ordered the NIH to restore, much damage has already been done. 'There's just an overwhelming sense of insecurity.' —Sierra Wilson, Ph.D. student, University of Pittsburgh Labs that still have funding are also working under high pressure and low morale. 'We're constantly asking our PI [principal investigator], 'Is everything going to be okay? Are we going to be safe?'' says R.K., an undergraduate student at a lab in the Midwest that's investigating treatments for a genetic disease. (R.K. asked to be identified by his initials, citing fear that speaking out could harm his future career.) At weekly meetings, he says, the lab's principal investigator has been pushing the team to publish more papers 'in order to show our progress to donor organizations.' If the researchers' NIH funding shrinks, he says, 'we would need to persuade our other donors for more money to make up the gap.' Applied across thousands of U.S. labs, these losses—both tangible and psychological—will add up, Pekosz says. 'We're going to see a massive downsizing of biomedical research efforts because there simply is not going to be the funding available to maintain the current level,' he says. Recent data suggest this is likely to prove correct. For example, according to a 2023 JAMA Health Forum paper, of the 356 drugs that gained Food and Drug Administration approval between 2010 and 2019, more than 84 percent received research funding from the NIH before approval. This research was powered by early-career workers: billions of dollars in NIH funding supported graduate students, postdocs and research staff who conducted the work. Under the current budget cuts, however, 'all of this is at risk,' says Fred Ledley, a co-author of the 2023 paper and a professor of natural and applied sciences at Bentley University. Deeply Personal The termination letter for Calimo's grant, which is not affected by Judge Young's ruling, said that it 'no longer [effectuated] agency priorities' and that 'research programs based primarily on artificial and non-scientific categories, including amorphous equity objectives, are antithetical to the scientific inquiry, do nothing to expand our knowledge of living systems, provide low returns on investment, and ultimately do not enhance health, lengthen life or reduce illness.' Not only did these claims completely contradict the original score that NIH grant reviewers gave Camilo's application, reading the letter made him feel like he was being 'attacked,' he says. Early-career grants are both crucial stepping stones to larger grants and recognition of a rising researcher's potential. The way the Trump administration's termination letters are worded 'delegitimates the scientists and the work they do,' Ranney says. 'There's often a deeply personal aspect.' 'I just feel very let down and betrayed by my country.' —Alex, postdoc, University of Colorado Sometimes, that personal aspect is literally about the researchers themselves. Sierra Wilson, a Ph.D. student at the University of Pittsburgh, assumed her liver-regeneration research would be safe from the cuts. But because Wilson is a first-generation college student from a low-income household, her funding came from a program that aimed to increase diversity in biomedical research, and according to the NIH spokesperson, that program is now 'expired.' When Wilson read her termination letter in late April, she suspected it must be related not to her research but to her classification as an underrepresented scholar. In her case, she says, the federal cuts appear to be targeting 'people themselves—which feels more discriminatory.' The NIH spokesperson did not respond to Scientific American's question about the allegation that the termination of grants in the now expired program appeared to be based on researchers' identity or background. According to the spokesperson, 'Grantees may appeal terminations for nonalignment with agency priorities.' Wilson sent an appeal request in May, but she does not expect a timely resolution, and to her knowledge, her grant is not affected by Judge Young's decision. University personnel who helped her with the appeals process told her that they expect she will have graduated by the time the NIH gets back to her. A number of junior researchers say all these blows are taking a heavy toll on their mental health. One of them is Alex, a postdoc at the University of Colorado, whose last name has been withheld for privacy at her request. Alex, who says she comes from a low socioeconomic background and served in the military before pursuing research developing flu vaccines, reports recurring nightmares about losing her postdoctoral job. She 'spirals' each time she sees bad news about science at stake, she says, and has recently developed blood pressure issues. 'I just feel very let down and betrayed by my country,' she says. 'I feel ashamed I even served it.' The Lost Generation of Scientists Scientists who are just entering their field can spark fresh ideas and bring an appetite for change. But dwindling funding and opportunities threaten to 'choke off' this influx of new talent—further constraining the already competitive job market—Pekosz says. He has even seen signs of the scientist-hiring drought spilling over into industry. His graduating Ph.D. students are struggling to secure jobs, he says, adding that his inbox is full of e-mails from prospective students as well as laid-off federal scientists seeking positions in his lab. Wilson has fading hopes for securing a job in academia when she graduates this fall. 'With all these grant and job terminations, the market is flooded, and people aren't hiring because [they don't know] how things will work out,' Wilson says. 'There's just an overwhelming sense of insecurity.' Many scientists, including early-career ones, are contemplating leaving the U.S. to find better support for their research. R.K., who plans to pursue a dual medical degree and Ph.D., is now considering applying to programs in Asia and Europe. Alex, likewise, is strongly thinking about leaving the country. 'I would love to be a PI,' she says. 'But there's no hope left here.' If available scientific talent continues to decline in the U.S., experts anticipate a potential domino effect on the economy. In 2024 every dollar invested in NIH research generated a $2.56 return, so the U.S. economy will likely feel the aftershocks of the recent cuts relatively quickly, Ranney says. In the longer term, scientific discoveries 'will start to stagnate,' she says. 'We need to recognize that we have a tremendous amount of power.' —Tyler Yasaka, medical and Ph.D. student, University of Pittsburgh There's also a likelihood that science fields will become a less appealing choice for incoming college students. 'I worry that we're going to see a loss of basic scientific skill and knowledge as fewer people go into science,' Ranney says. If the pipeline of new talent slows, the nation's position as a global leader in science will be difficult to maintain—or to recover once it's gone, she says. It's going to be impossible to replace all the lost federal funding, Ranney says. The remaining hope, then, is that 'we can reverse course,' she says. Some scientists are uniting and pushing back. Tyler Yasaka, a dual medical and Ph.D. student at the University of Pittsburgh, is part of an informal committee at the University of Pittsburgh Medical Center's Hillman Cancer Center that's brainstorming actions researchers and students can take, such as advocating for science in front of elected officials at Capitol Hill. He is also independently launching a podcast to share scientists' experiences with funding. 'I think most scientists aren't comfortable speaking out publicly, but if we value democracy, we have an obligation to use our voices,' Yasaka says. 'We need to recognize that we have a tremendous amount of power.' Fortunately for Camilo, his university has found institutional funds to support the remainder of his Ph.D. But he no longer sees a clear path forward after graduation to continue his research on HIV and LGBTQ+ health among Latinos in the U.S.—public health issues that are personally important to him. 'It's sad and upsetting,' he says. 'I do not want to give up on my community.'
Newsweek
4 hours ago
- Newsweek
The Bulletin June 21, 2025
The rundown: The issue of animal testing is something most Americans agree on: it needs to change and gradually be stopped. Since President Donald Trump began his second term, his administration has been making moves to transform and reduce animal testing in country. Find out what steps are being taken. Why it matters: In April, the Food and Drug Administration (FDA) said that its animal testing requirement will be "reduced, refined, or potentially replaced" with a range of approaches, including artificial intelligence-based models, known as New Approach Methodologies or NAMs data. The Trump administration's efforts to tackle the issue of animal testing appear to be a step in the right direction, according to experts who spoke with Newsweek. Read more in-depth coverage: Over 300 Animals Removed From US Safari After Decade of Red Flags TL/DR: Millions of animals each year are killed in U.S. laboratories as part of medical training and chemical, food, drug and cosmetic testing. What happens now? A Department of Health and Human Services (HHS) official told Newsweek: "The agency is paving the way for faster, safer, and more cost-effective treatments for American patients.' Deeper reading How Animal Testing in US Could Be Transformed Under Trump
